Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 11

1.

RET mutations in exons 13 and 14 of FMTC patients.

Bolino A, Schuffenecker I, Luo Y, Seri M, Silengo M, Tocco T, Chabrier G, Houdent C, Murat A, Schlumberger M, et al.

Oncogene. 1995 Jun 15;10(12):2415-9.

PMID:
7784092
2.

Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804.

Lombardo F, Baudin E, Chiefari E, Arturi F, Bardet S, Caillou B, Conte C, Dallapiccola B, Giuffrida D, Bidart JM, Schlumberger M, Filetti S.

J Clin Endocrinol Metab. 2002 Apr;87(4):1674-80.

PMID:
11932300
3.

New era: prophylactic surgery for patients with multiple endocrine neoplasia-2a.

Gosnell JE, Sywak MS, Sidhu SB, Gough IR, Learoyd DL, Robinson BG, Delbridge LW.

ANZ J Surg. 2006 Jul;76(7):586-90.

PMID:
16813623
4.

Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation.

Nilsson O, Tisell LE, Jansson S, Ahlman H, Gimm O, Eng C.

JAMA. 1999 May 5;281(17):1587-8. No abstract available.

PMID:
10235148
5.

Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.

Learoyd DL, Gosnell J, Elston MS, Saurine TJ, Richardson AL, Delbridge LW, Aglen JV, Robinson BG.

Clin Endocrinol (Oxf). 2005 Dec;63(6):636-41.

PMID:
16343097
6.

Germline homozygous mutations at codon 804 in the RET protooncogene in medullary thyroid carcinoma/multiple endocrine neoplasia type 2A patients.

Lesueur F, Cebrian A, Cranston A, Leyland J, Faid TM, Clements MR, Robledo M, Whittaker J, Ponder BA.

J Clin Endocrinol Metab. 2005 Jun;90(6):3454-7. Epub 2005 Mar 1.

PMID:
15741265
7.

Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.

Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M.

Oncogene. 1997 Jul 24;15(4):393-402.

8.

Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.

Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M.

Oncogene. 1999 Jul 1;18(26):3919-22.

9.

RET codon 804 mutations in multiple endocrine neoplasia 2: genotype-phenotype correlations and implications in clinical management.

Mukherjee S, Zakalik D.

Clin Genet. 2011 Jan;79(1):1-16. doi: 10.1111/j.1399-0004.2010.01453.x. Review.

PMID:
20497437
10.

Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?

Frohnauer MK, Decker RA.

Surgery. 2000 Dec;128(6):1052-7;discussion 1057-8.

PMID:
11114642
11.

Supplemental Content

Support Center